132
Participants
Start Date
May 24, 2023
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
Enzalutamide
Second-generation androgen pathway inhibitor (ARAT), oral tablet
Standard of Care SBRT and ADT
Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)
RECRUITING
Princess Margaret Cancer Center, Toronto
ACTIVE_NOT_RECRUITING
Sunnybrook Research Institute, Toronto
Collaborators (1)
Astellas Pharma Inc
INDUSTRY
University Health Network, Toronto
OTHER